Steroidal CYP17 inhibitors for prostate cancer treatment: from concept to clinic

Jorge A. R. Salvador; Vania M. Moreira; Samuel M. Silvestre

doi:10.5772/52290

Steroidal CYP17 inhibitors for prostate cancer treatment: from concept to clinic

Jorge A. R. Salvador, Vania M. Moreira, Samuel M. Silvestre

Strathclyde Institute Of Pharmacy And Biomedical Sciences

Research output: Chapter in Book/Report/Conference proceeding › Chapter

9 Downloads (Pure)

Abstract

The successful application of therapeutic strategies to block the known growth stimulation property of estrogen in breast cancer, namely the aromatase (CYP19) inhibitors formestane (4-OH) and exemestane (Aromasin) [1], has paved the way for the investigation of inhibitors of other P450 enzymes that might impart the growth of hormone-dependent cancers [2]. Cytochrome P450 17α-hydroxylase,C17,20-lyase (CYP17) is at the crossroads of androgen and corticoid biosynthesis and has become a valuable target in prostate cancer (PC) treatment [3-8]. Androgens, which are produced in steroidogenic tissues, bind to the androgen receptor (AR) and initiate transcription which in turn results in the synthesis of prostate-specific proteins, as well as in cell proliferation. Systemic ablation of androgen by castration, either surgical or chemical, is highly effective in treating PC when the disease is hormone-dependent.

Original language	English
Title of host publication	Advances in Prostate Cancer
Place of Publication	London
Pages	275-304
Number of pages	30
DOIs	https://doi.org/10.5772/52290
Publication status	Published - 16 Jan 2013

Keywords

CYP17
CYP17 inhibitors
prostate cancer treatment

Access to Document

10.5772/52290Licence: CC BY 3.0

Salvador-etal-Intech-2012-Steroidal-CYP17-inhibitors-for-prostrate-cancer-treatmentFinal published version, 736 KBLicence: CC BY 3.0

Fingerprint Dive into the research topics of 'Steroidal CYP17 inhibitors for prostate cancer treatment: from concept to clinic'. Together they form a unique fingerprint.

Cite this

Salvador, J. A. R., Moreira, V. M., & Silvestre, S. M. (2013). Steroidal CYP17 inhibitors for prostate cancer treatment: from concept to clinic. In Advances in Prostate Cancer (pp. 275-304). London. https://doi.org/10.5772/52290

@inbook{f84de5623a84404f951ce08ed70aaa09,

title = "Steroidal CYP17 inhibitors for prostate cancer treatment: from concept to clinic",

abstract = "The successful application of therapeutic strategies to block the known growth stimulation property of estrogen in breast cancer, namely the aromatase (CYP19) inhibitors formestane (4-OH) and exemestane (Aromasin) [1], has paved the way for the investigation of inhibitors of other P450 enzymes that might impart the growth of hormone-dependent cancers [2]. Cytochrome P450 17α-hydroxylase,C17,20-lyase (CYP17) is at the crossroads of androgen and corticoid biosynthesis and has become a valuable target in prostate cancer (PC) treatment [3-8]. Androgens, which are produced in steroidogenic tissues, bind to the androgen receptor (AR) and initiate transcription which in turn results in the synthesis of prostate-specific proteins, as well as in cell proliferation. Systemic ablation of androgen by castration, either surgical or chemical, is highly effective in treating PC when the disease is hormone-dependent.",

keywords = "CYP17 , CYP17 inhibitors, prostate cancer treatment",

author = "Salvador, {Jorge A. R.} and Moreira, {Vania M.} and Silvestre, {Samuel M.}",

year = "2013",

month = "1",

day = "16",

doi = "10.5772/52290",

language = "English",

isbn = "978-953-51-0932-7",

pages = "275--304",

booktitle = "Advances in Prostate Cancer",

}

TY - CHAP

T1 - Steroidal CYP17 inhibitors for prostate cancer treatment

T2 - from concept to clinic

AU - Salvador, Jorge A. R.

AU - Moreira, Vania M.

AU - Silvestre, Samuel M.

PY - 2013/1/16

Y1 - 2013/1/16

N2 - The successful application of therapeutic strategies to block the known growth stimulation property of estrogen in breast cancer, namely the aromatase (CYP19) inhibitors formestane (4-OH) and exemestane (Aromasin) [1], has paved the way for the investigation of inhibitors of other P450 enzymes that might impart the growth of hormone-dependent cancers [2]. Cytochrome P450 17α-hydroxylase,C17,20-lyase (CYP17) is at the crossroads of androgen and corticoid biosynthesis and has become a valuable target in prostate cancer (PC) treatment [3-8]. Androgens, which are produced in steroidogenic tissues, bind to the androgen receptor (AR) and initiate transcription which in turn results in the synthesis of prostate-specific proteins, as well as in cell proliferation. Systemic ablation of androgen by castration, either surgical or chemical, is highly effective in treating PC when the disease is hormone-dependent.

AB - The successful application of therapeutic strategies to block the known growth stimulation property of estrogen in breast cancer, namely the aromatase (CYP19) inhibitors formestane (4-OH) and exemestane (Aromasin) [1], has paved the way for the investigation of inhibitors of other P450 enzymes that might impart the growth of hormone-dependent cancers [2]. Cytochrome P450 17α-hydroxylase,C17,20-lyase (CYP17) is at the crossroads of androgen and corticoid biosynthesis and has become a valuable target in prostate cancer (PC) treatment [3-8]. Androgens, which are produced in steroidogenic tissues, bind to the androgen receptor (AR) and initiate transcription which in turn results in the synthesis of prostate-specific proteins, as well as in cell proliferation. Systemic ablation of androgen by castration, either surgical or chemical, is highly effective in treating PC when the disease is hormone-dependent.

KW - CYP17

KW - CYP17 inhibitors

KW - prostate cancer treatment

U2 - 10.5772/52290

DO - 10.5772/52290

M3 - Chapter

SN - 978-953-51-0932-7

SP - 275

EP - 304

BT - Advances in Prostate Cancer

CY - London

ER -